Dianthus Therapeutics, Inc. /DE/ Proceeds from Common Stock Issued
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Proceeds from Common Stock Issued of $120.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for the quarter ending 2026-06-30 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for the quarter ending 2026-03-31 was $120.00K, a 6.98% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for the quarter ending 2025-12-31 was $1.00K.
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for the quarter ending 2025-09-30 was $187.00K.
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for fiscal 2025 was $317.00K.
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for fiscal 2024 was $0.00.
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ proceeds from issuance of common stock for fiscal 2022 was $2.90M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $120.00K 10-Q · filed 2026-08-04 | $121.00K derived: sum of 3 quarters · filed 2026-08-04 | $308.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $120.00K 10-Q · filed 2026-05-05 | $121.00K derived: sum of 2 quarters · filed 2026-05-05 | $308.00K derived: sum of 3 quarters · filed 2026-05-05 | $308.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $188.00K derived: sum of 2 quarters · filed 2026-03-09 | $188.00K derived: sum of 3 quarters · filed 2026-08-04 | $317.00K 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $187.00K derived: sum of 2 quarters · filed 2026-08-04 | $316.00K 10-Q · filed 2025-11-05 | $316.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $129.00K 10-Q · filed 2026-08-04 | $129.00K derived: sum of 3 quarters · filed 2026-08-04 | $129.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $129.00K 10-Q · filed 2026-05-05 | $129.00K derived: sum of 2 quarters · filed 2026-05-05 | $129.00K derived: sum of 3 quarters · filed 2026-05-05 | $129.00K derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 | $39.20M 10-K · filed 2025-03-11 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | ||||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 | ||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.90M 10-K · filed 2023-03-23 | |||||
| 2022-09-30 | $2.90M 10-Q · filed 2022-11-03 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 | |||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $0.00 derived: sum of 2 quarters · filed 2022-03-08 | $64.86M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $64.86M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $64.60M 10-K · filed 2021-03-03 | $64.60M 10-K · filed 2022-03-08 | $64.86M 10-Q · filed 2021-08-05 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $0.00 derived: sum of 2 quarters · filed 2021-03-03 | $60.87M 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $60.87M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $60.87M 10-Q · filed 2020-08-06 | ||||||
| 2019-05-31 | $60.30M 10-K · filed 2021-03-03 | ||||||
| 2019-05-06 | $60.30M 10-K · filed 2021-03-03 | ||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $93.00M 10-K · filed 2020-03-03 | |||||
| 2018-09-30 | $93.00M 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |